Every 10-Q that The Chemours Company (CC) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow CC and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CC filings page.
The Chemours Company reported Q2 2026 net sales of $1.591 billion and a net loss attributable to Chemours of $274 million, or $1.81 per basic and diluted share. For the first six months of 2026, net sales were $2.972 billion and the net loss was $303 million.
Thermal & Specialized Solutions generated $591 million of Q2 net sales and Titanium Technologies $661 million. Operating cash flow for the first half of 2026 was $114 million, while purchases of property, plant, and equipment totaled $93 million.
At June 30, 2026, Chemours reported total assets of $7.150 billion, total current liabilities of $1.861 billion, long‑term debt of $3.838 billion and total Chemours stockholders’ equity of $(49) million. The company held $671 million of unrestricted cash and had $953 million available under its revolving credit facility, and stated it believes it has sufficient liquidity to timely settle its current liabilities through at least the end of August 2027, although adverse outcomes in legal or environmental matters could have a material adverse effect on liquidity. Chemours also revised certain 2025 figures for immaterial errors primarily related to the timing of income tax expense recognition.
The Chemours Company reported first-quarter 2026 net sales of $1.381 billion, slightly above $1.368 billion a year earlier, but swung to a larger net loss of $29 million versus a $5 million loss. Basic and diluted loss per share was $0.19, compared with $0.03.
Gross profit declined to $212 million from $236 million as cost of goods sold increased. Results included $13 million of restructuring, asset-related, and other charges and a $9 million loss on extinguishment of debt, partly offset by $22 million of other income, helped by licensing Zelan repellents.
Operating cash outflow improved to $44 million from $112 million. At March 31, 2026, Chemours held $563 million of cash and cash equivalents, against $4.183 billion of total debt and $7.051 billion of total liabilities. Accrued litigation totaled $491 million, largely tied to asbestos and PFAS matters, and management highlighted that adverse legal or environmental outcomes could materially affect liquidity despite available cash and a $953 million undrawn revolving credit facility.
Chemours (CC) reported Q3 2025 results with net sales of $1,495 million versus $1,508 million a year ago. The company returned to profitability with net income of $60 million, or $0.40 per diluted share, compared to a net loss of $32 million in Q3 2024. Gross profit was $233 million, and selling, general and administrative expense declined to $109 million.
For the first nine months, net sales were $4,478 million and net loss was $(325) million ($(2.16) per share). Operating cash flow improved to $127 million year-to-date, versus $(771) million in the prior-year period. As of September 30, 2025, cash and cash equivalents were $613 million, with $953 million available under the revolving credit facility and current liabilities of $1,880 million. Total equity was $300 million. The company recorded a quarterly dividend of $0.0875 per share. Management revised prior periods for immaterial errors, reducing 2024 year-to-date net income by $13 million.
Chemours (CC) posted a sharp swing to loss in Q2-25. Net sales rose 3.9% YoY to $1.615 billion, but gross profit contracted 9.7% to $278 million and SG&A ballooned to $437 million (vs. $154 million), driving a GAAP net loss of $380 million (-$2.54 per diluted share) versus $60 million profit a year ago. Six-month sales improved 2.3% to $2.983 billion, yet the company recorded a H1-25 loss of $384 million (-$2.56 per share) against $113 million income in H1-24.
Cash from operations was a modest -$19 million, far better than the -$910 million outflow reported in the prior-year period, helped by smaller working-capital drains. Free cash flow remained negative as Chemours spent $127 million on capex. Cash and equivalents fell to $502 million from $713 million at year-end, while long-term debt inched up to $4.102 billion. Total equity shrank to $239 million, reflecting the loss and a dividend cut to $0.0875 per share (vs. $0.25 last year).
The company cites $954 million unused capacity on its revolving credit facility and believes liquidity is adequate through August 2026, but warns that adverse outcomes in PFAS and other legal/environmental matters could be material. Management revised prior-period financials for presentation errors; impacts were immaterial.